We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
The S&P/ASX 200 Index (ASX: XJO) is having a good session on Thursday. In afternoon trade, the...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is on form again on Monday. At the time of writing, the benchm...
Read ArticleASX pares back early gains to lift 0.32pc Healthcare, tech, utilities drive gains Resources sector...
Read ArticleOncosil will accelerate the rollout of its targeted radiation device after promising trial results...
Read ArticleIt looks set to be a day to forget for shareholders of one ASX All Ords stock. That's because in ear...
Read ArticleAustralian shares are heading towards a -0.43% dip at open on Wednesday, with global markets edgy ah...
Read ArticleCervical cancer detection play Truscreen says its year is off to a good start PYC Therapeutics ente...
Read ArticleIf you have a high tolerance for risk, then it could be worth considering the speculative ASX stock...
Read ArticleBiotechs can be a risky investment, but where the risks are high, so potentially are the gains. Wils...
Read ArticleHighlights ASX eases amid US Federal Reserve developments Gold stocks gain traction as gold pri...
Read ArticleASX slips just 12.3 points, remaining near all-time high Healthcare leads losses as Trump raises ta...
Read ArticleHighlights ASX 200 index trades close to record high Gains led by materials and coal stoc...
Read ArticleNanosonics has launched tweaked versions of its Trophon medical probe steriliser Amplia shares soa...
Read ArticleHighlights GYG, MEK, and PYC listed on ASX 200 show strong earnings momentum and executive bac...
Read ArticleThe ASX 200 closed up 0.1% at 8,361 points. IT was the best performing sector, followed by Materi...
Read ArticleHighlights Develop Global, Guzman y Gomez, and PYC Therapeutics feature among notable ASX grow...
Read ArticleASX heath sector up 1.9%, trailing ASX 200’s 2% gain in short week revival Sleep-related respirat...
Read ArticleNova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the ba...
Read ArticleHighlights: Australian market experiences a modest rise, with the technology sector maintainin...
Read ArticleHighlights: Several ASX-listed companies have demonstrated high earnings expansion alongside s...
Read ArticleA cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr...
Read ArticleASX small-cap shares are slightly outperforming in 2025, with the S&P/ASX Small Ordinaries Index...
Read ArticleHighlights ASX200 faces a 0.36% decline following new US tariffs on Australian aluminum and stee...
Read ArticleThe ASX200 has been down 0.36% at 8,480 points through trade today. The local bourse has reacted...
Read ArticleAnsell is expanding its manufacturing to be less reliant on China Mayne Pharma pre-announces a st...
Read ArticleThe ASX200 has hit yet another all-time high of 8,566 points in morning trade. The record was dri...
Read ArticlePYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating...
Read ArticleThe ASX200 has been up 0.23% at 8,330 points. Donald Trump will be sworn in as the 47th President...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is back on form and pushing higher on Monday. In afternoon tra...
Read ArticleImmutep, Percheron and PYC feature in clinical trial updates Control Bionics guides to higher reven...
Read ArticlePYC Therapeutics (ASX:PYC) has nominated a fourth clinical drug candidate, PYC-002, targeting Phelan...
Read ArticleASX healthcare shares were in the red yesterday, with the S&P/ASX 200 Health Care Index (ASX:...
Read ArticleS&P/ASX All Ords (ASX: XAO) shares soared 3.29% in November amid an early start to the tradition...
Read ArticlePYC Therapeutics Ltd (ASX:PYC) – a clinical biotech company which is progressing the first drug cand...
Read ArticleThe ASX200 closed down 0.4% at 8,131 points. The Reserve Bank Board has kept interest rates on ho...
Read ArticlePYC Therapeutics (ASX:PYC) has has been approved to escalate doses of its drug candidate VP-001, tre...
Read ArticleBiotech player PYC Therapeutics (ASX:PYC) has dosed its first patient in a clinical trial seeking to...
Read ArticlePYC Therapeutics (ASX:PYC) has announced significant progress in its efforts to develop RNA-based pr...
Read ArticleMixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch i...
Read ArticleASX closes higher led by strong mining sector Wisetech and Mineral Resources suffer heavy losses a...
Read ArticleParadigm Biopharmaceuticals says it is ready to apply to the US regulator to start its delayed phas...
Read ArticleASX set to rise on Monday after strong Wall Street gains Netflix shares up 11pc on strong profits T...
Read ArticleThe ASX200 closed up nearly 0.95% at 8,203 points, amid China’s stimulus news and as iron ore rose t...
Read ArticleIt's been a big day for several ASX All Ords shares, with three companies in particular seeing stron...
Read ArticleHealth Check is renowned biotech journo Tim Boreham’s daily wrap covering morning movers and shakers...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticlePYC Therapeutics Ltd (ASX:PYC) has announced that the US Food and Drug Administration (FDA) has gran...
Read ArticlePYC starts human trials for PYC-001 to treat rare eye disease OncoSil device successfully treats fi...
Read ArticleCanaccord rates PYC a Buy with a target price of $0.22, possibly rising to $1.20 PYC is advancing R...
Read ArticleThe ASX200 closed up 0.46% at 7,813 points, as the market continues to recoup last weeks losses....
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another solid gain....
Read ArticleTryptamine’s psilocybin trial indicates potential for treating fibromyalgia Actinogen says Xanamem...
Read ArticleThe ASX 200 dropped over 3% on Monday amid recession fears and weak US data Over $100 billion was w...
Read ArticlePYC’s VP-001 improves vision in ongoing eye disease trials LTR Pharma’s Spontan is now available fo...
Read ArticleWestern Australia wanting to diversity beyond resources and become a global leader in health and me...
Read ArticleBiotechnology company PYC Therapeutics Ltd (ASX:PYC) has begun a follow-up study in the United State...
Read ArticleImricor completes installation of iCMR capital equipment at Lausanne University Hospital in Switzer...
Read ArticleFor biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The...
Read ArticleThe ASX200 closed the day up, about half a per cent, leading up to the King’s birthday public holida...
Read ArticleThe ASX200 is trading above expectations, up 0.35%. The discretionary sector leads the way, up 1....
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. In afternoon...
Read Article07 Jun 2024 - A snapshot of the stocks on the move, featuring PYC Therapeutics (ASX:PYC), Caprice Re...
Read ArticleTo register for today's webinar click here. PYC Therapeutics (ASX:PYC) announces that their fourth...
Read ArticlePYC Therapeutics (ASX: PYC) has made a breakthrough with its main drug candidate for the potential t...
Read ArticleBiotechnology company Pyc Therapeutics Ltd (ASX:PYC) has announced that it has been able to restore...
Read ArticleInvestors with a high risk tolerance might want to consider adding the two ASX penny stocks in this...
Read ArticleIt has been a tough finish to the week for the S&P/ASX 200 Index (ASX: XJO). In afternoon trad...
Read ArticlePYC Therapeutics gets FDA approval PYC Therapeutics (ASX:PYC) has received an Orphan Drug Designatio...
Read ArticleIt can be useful for investors to keep an eye on which shares have experienced meaningful insider bu...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a day to remember on Thursday. In afternoon trade, t...
Read ArticlePYC Therapeutics (ASX:PYC) has announced that it has completed dosing in patient cohort 4 (7...
Read ArticlePYC Therapeutics (ASX:PYC) says that one of its candidates for a blinding eye disease of chi...
Read ArticleThe ASX200 closed the day up more than a per cent (1.08%). All sectors bar one finished in the gr...
Read ArticleThe ASX200 is up nearly a per cent – in a harmonious flow with futures predictions. Every sector...
Read ArticlePYC Therapeutics (ASX:PYC) has completed Dose Range Finding (DRF) studies for its investigational dr...
Read ArticleIt’s been three consecutive months that US inflation data has come in higher than expected and, with...
Read ArticlePYC Therapeutics (ASX:PYC) has announced the successful closure of the institutional compone...
Read ArticleHere’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 2...
Read ArticlePYC Therapeutics (ASX:PYC) has announced the results of a study conducted in three-dimension...
Read ArticlePYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Ki...
Read Article4DX surges more than 50pc after an update from the US PYC Therapeutic said its fourth drug candidat...
Read ArticlePYC Therapeutics (ASX:PYC) has held a pre-IND meeting with the US FDA and announced it has a...
Read ArticlePYC to take ADOA drug to human clinical trials Imugene provides update of its Phase 1 MAST (Metasta...
Read ArticlePYC Therapeutics (ASX:PYC) has announced that the Safety Review Committee (SRC) governing on...
Read ArticlePYC Therapeutics (ASX:PYC) has completed dosing for patients in cohort one of the Platypus c...
Read ArticleASX to open higher despite a drop on Wall Street Tonight’s US CPI data weighs on markets These two...
Read ArticlePYC receives Fast Track designation from the US FDA BCAL Diagnostics announces breakthrough results...
Read ArticlePYC Therapeutics to advance to Phase 2 clinical trial Osteopore announced new CEO and non-executive...
Read ArticlePYC Therapeutics (PYC) doses the first patient with drug candidate VP-001, designed to treat blindin...
Read ArticleASX falls 0.17% ahead of Chalmers dropping The Budget on the nation Financials led the pack today,...
Read ArticleCardieX jumps 16pc after getting FDA clearance for CONNEQT Pulse CONNEQT Pulse is a world first mul...
Read ArticlePYC Pharmaceuticals (PYC) lands approval from the US FDA to begin human trials of a new drug to trea...
Read ArticleRhythm plunged 45% this morning after announcing some TGA news The FDA has cleared PYC Therapeutics...
Read ArticleSonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer ...
Read ArticlePYC Therapeutics (PYC) completes single-dose toxicology of its investigational Retinitis Pigmentosa...
Read ArticleHighlights: The ASX 200 benchmark index closed up today, gaining 0.41% to end at 6,496.20 points...
Read ArticlePYC Therapeutics (PYC) adds a third drug program for the treatment of Phelan McDermid Syndrome (PMS)...
Read ArticlePYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical...
Read ArticleThe ASX 200 will open higher on Tuesday despite another selloff on Wall Street Investors dump risky...
Read ArticleHighlights PYC Therapeutics has completed its pharmacokinetic (PK) studies in Non-Human Primates...
Read ArticleBiotech company PYC Therapeutics (PYC) has increased its stake in Vision Pharma to 93.5 per cent T...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticlePYC Therapeutics (ASX:PYC) says it has completed a key translational milestone for its RNA p...
Read ArticleThe hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.30% at the time of writing, compared to the broader inde...
Read ArticleThe ASX posted steady gains to start the week on Monday, with investors preferences leaning towards...
Read ArticlePharmAust has had a busy and productive quarter, setting the foundations for the commercialisation o...
Read ArticleSummary The S&P/ASX200ended 60 points or 0.31% higher at 7,354. The index gained as much as...
Read ArticleSummary The S&P/ASX200 traded higher by 20 points or 0.27% at 7,352 by the afternoon. The i...
Read ArticleThe ASX finished in positive territory, although short of an all-time high. The ASX 200 closed 0.15...
Read ArticlePYC Therapeutics (ASX:PYC), a company developing RNA therapeutics for inherited diseases, ha...
Read ArticleThe ASX 200 close 0.19 per cent lower than Friday at 7,282 points and the ASX Emerging Companies Ind...
Read ArticleThe PYC Therapeutics Ltd (ASX: PYC) share price has risen 170% in a year and 13% this month, follow...
Read ArticlePYC Therapeutics (ASX:PYC), a biotechnology company developing precision RNA therapeutics, h...
Read ArticleThe ASX finished in the red today dragged down by resources and energy. Materials and Energy stocks...
Read ArticleSource: GoYong,Shutterstock Summary PYC Therapeutics’ investigational drug, VP-001, has restore...
Read ArticlePYC Therapeutics (ASX:PYC), a biotechnology company developing a new generation of precision...
Read ArticleThe PYC Therapeutics Ltd (ASX: PYC) share price leapt 9% higher to 18 cents today before slipping t...
Read ArticleS&P Dow Jones Indices has announced the quarterly rebalance of the entire S&P/ASX index hier...
Read ArticleZelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a...
Read ArticleHere it is – your weekly look at the stocks fund managers are buying (and selling). Trading Places i...
Read ArticleDrug development company, PYC Therapeutics (PYC) has added six new precision medicines to its retin...
Read ArticlePYC Therapeutics (PYC) recently finalised its lead drug molecule in the final quarter of 2019 Its l...
Read ArticleThere are many reasons why a company might change its name, from being taken over to hiding a shady...
Read ArticleDid the doc say to take one pill twice daily, or two tablets once daily? When it comes to correct me...
Read ArticleDid you know that a hard-working stallion ejaculates 100 times more sperm than the average bloke? Gi...
Read ArticleOne director has this week put more skin in the game to take his family’s total stake to over $20m —...
Read ArticleEver since the advent of TV, worried parents have cautioned their kids that too much time in front o...
Read ArticleBiotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading...
Read ArticleOn Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers wi...
Read ArticleA drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to b...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleAustralia is known to have one of the world’s best health system, which provides quality, safe and r...
Read ArticlePerth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pi...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleBiotechnology company Phylogica (ASX: PYC) has unveiled favourable lab results in relation to its ti...
Read ArticleMedical tech company Phylogica (ASX: PYC) has cleared an important hurdle in the development of its...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
